Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Nova Mentis Life Science Corp. (C:NOVA)

Business Focus: Biotechnology & Medical Research (NEC)

May 17, 2022 10:53 am ET
Healthcare Breakthroughs: IDRA, NMLSF, LMLLF, BBI; Life Sciences Leaders Report Latest Advances in Novel Therapeutics for Autism, Oncology, Autoimmune Diseases, and Glaucoma
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Brickell Biotech (NASDAQ: BBI), Idera Pharmaceuticals...
May 13, 2022 10:08 am ET
BioMed Stocks On the Move: Nova Mentis, PolarityTE, Veru, and PharmaDrug; Life Sciences Leaders Report Latest Advances in Regenerative Tissue Technology, Novel Therapeutics for Oncology, COVID, Glauco
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), PolarityTE, Inc. (NASDAQ: PTE) Veru Inc. (NASDAQ:...
May 12, 2022 08:30 am ET
Nova Mentis Welcomes Autism Behaviour Analyst to its Science Team
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to welcome John Molinaro, a Board Certified Behaviour Analyst specializing in autism spectrum disorder therapy, to its Scientific Advisory Board.
May 04, 2022 10:53 am ET
BioMed Momentum: NMLSF, BBI, LMLLF, VERU; Life Sciences Leaders Report Latest Advances in New Drug Development for Autism, COVID-19, Oncology, and Glaucoma
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Veru Inc. (NASDAQ: VERU), PharmaDrug (OTC: LMLLF) (CSE:...
May 04, 2022 08:30 am ET
Nova Mentis Psilocybin Manufacturer Receives Approved Health Canada Importation Permit
Phase 2A Microdose Clinical Study Capsules to be Manufactured
Apr 28, 2022 08:30 am ET
Nova Mentis Sees Rapid Enrollment in Autism Study
Databank to focus on mRNA neuroinflammatory markers and serotonin neuro-transmitters
Apr 26, 2022 10:46 am ET
BioMed Momentum: AGRX, NMLSF, LMLLF, VERU; Life Sciences Leaders Report Latest Advances in New Drug Development for COVID-19, Oncology, Glaucoma, and Autism
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Veru Inc. (NASDAQ: VERU), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Agile Therapeutics (NASDAQ:...
Apr 25, 2022 09:24 am ET
Next Super Stocks on the Move: NEXCF, NMLSF, OGGFF, LMLLF; Driving Disruptive Innovation with Explosive Revenue Growth Potential in Biopharma, E-Commerce, Metaverse, and Plant-Based Brands
Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK investor conferences, and online events which engage...
Apr 19, 2022 09:53 am ET
Healthcare Breakthroughs: AGRX, NMLSF, BBI, LMLLF; BioMed Leaders Report Latest Advances in New Drug Development for Women’s Health, Autism, Glaucoma, and Cancer Therapeutics
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Brickell Biotech (NASDAQ: BBI), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Agile Therapeutics...
Apr 18, 2022 08:56 am ET
Next Super Stocks on the Move: NMLSF, NEXCF, OGGFF, MKTDF; Leading Innovation in Carbon Credits, Metaverse, Plant-Based Brands, and Biopharma.
Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK investor conferences, which engage an estimated 12...
Apr 14, 2022 09:57 am ET
BioMed Momentum: VERU, NMLSF, PHRX, CRXT; Life Sciences Leaders Report Latest Advances in New Drug Development for COVID-19, Cancers, Glaucoma, and Autism
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: Veru Inc. (NASDAQ: VERU), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Clarus Therapeutics (NASDAQ:...
Apr 13, 2022 10:00 am ET
Healthcare Breakthroughs: Atai, Nova Mentis, PolarityTE, and LIXTE; Biomed Leaders Report Latest Advances in Regenerative Tissue Technology, Psychedelics, and New Therapeutics for Autism, Mental Healt
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: PolarityTE, Inc. (NASDAQ: PTE), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), atai Life Sciences N.V....
Apr 12, 2022 08:58 am ET
BioMed Stocks On the Move: Nova Mentis, PolarityTE, Biodesix and PharmaDrug; Life Sciences Leaders Report Latest Advances in Regenerative Tissue Technology, New Drugs for Cancers, Glaucoma, and Autism
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: PolarityTE, Inc. (NASDAQ: PTE) Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Biodesix, Inc. (NASDAQ:...
Apr 11, 2022 10:41 am ET
Healthcare Breakthroughs: Veru, Nova Mentis, Phio, and PharmaDrug; Visionary CEOs Report Latest Advances in New Drug Development for COVID-19, Cancers, Glaucoma, and Autism
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Phio Pharmaceuticals (NASDAQ: PHIO), Veru Inc....
Apr 11, 2022 09:47 am ET
BioMed Leaders: Hoth Therapeutics, Nova Mentis Life Sciences, Tonix Pharmaceuticals, and MedAvail; Visionary CEOs Report Latest Advances in Novel Therapeutics for Autism, Cancer, and Fibromyalgia, and
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Hoth Therapeutics (NASDAQ: HOTH), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Tonix...
Apr 07, 2022 08:30 am ET
Nova Mentis to Produce Psilocybin Capsules for Phase 2A Clinical Study
Manufacturing Contract with the Toronto Institute of Pharmaceutical Technology
Mar 23, 2022 08:30 am ET
Nova Mentis Begins Enrollment in North American Autism Study
VANCOUVER, BC, March 23, 2022 /PRNewswire/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to announce that it has begun the patient enrollment process for its North American Observational study: Establishing a Diagnostic and Therapeutic Index in Autism Spectrum Disorder (ASD) and Fragile X Syndrome (FXS).
Mar 23, 2022 08:30 am ET
Nova Mentis Begins Enrollment in North American Autism Study
VANCOUVER, BC, March 23, 2022 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to announce that it has begun the patient enrollment process for its North American Observational study: Establishing a Diagnostic and Therapeutic Index in Autism Spectrum Disorder (ASD) and Fragile X Syndrome (FXS).
Mar 15, 2022 08:30 am ET
Nova Mentis Announces Closing of Non-Brokered Financing
VANCOUVER, BC, March 15, 2022 /PRNewswire/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it has completed a non-brokered private placement financing for total gross proceeds of $1,483,500 (the "Placement").
Mar 15, 2022 08:30 am ET
Nova Mentis Announces Closing of Non-Brokered Financing
VANCOUVER, BC, March 15, 2022 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it has completed a non-brokered private placement financing for total gross proceeds of $1,483,500 (the "Placement").
Feb 16, 2022 07:00 am ET
Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism
VANCOUVER, BC, Feb. 16, 2022 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that Nova Mentis successfully completed an oral microdose psilocybin preclinical study, in the laboratory of Dr. Viviana Trezza, Rome Tre University, Rome, Italy. The results exceeded all expectations with the findings that a very low dose of the Company's proprietary psilocybin significa
Feb 16, 2022 07:00 am ET
Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism
VANCOUVER, BC, Feb. 16, 2022 /PRNewswire/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that Nova Mentis successfully completed an oral microdose psilocybin preclinical study, in the laboratory of Dr. Viviana Trezza, Rome Tre University, Rome, Italy. The results exceeded all expectations with the findings that a very low dose of the Company's proprietary psilocybin si
Jan 27, 2022 02:01 am ET
Nova Mentis and KGK Science Form Tactical Partnership
The Companies Plan to Jointly Submit a Psilocybin Clinical Trial Application to Health Canada
Jan 12, 2022 07:30 am ET
Nova Mentis Provides Corporate Update - 2022 Planned Catalysts
VANCOUVER, BC, Jan. 12, 2022 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders reviews its 2021 drug development accomplishments and its planned 2022 steps towards drug approval and commercialization.
Dec 31, 2021 07:30 am ET
Nova Mentis Welcomes New CFO Rebecca Hudson
VANCOUVER, BC, Dec. 31, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce Rebecca Hudson has joined NOVA as its Chief Financial Officer, adding corporate finance, accounting and risk management experience to the Company's management team.
Dec 16, 2021 07:30 am ET
Nova Mentis and Mycrodose Therapeutics Announce Major Milestone with Transdermal Technology for Fragile X Syndrome Clinical Program
VANCOUVER, BC, Dec. 16, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, and Mycrodose Therapeutics ("Mycrodose"), a US pharmaceutical company focused on developing advanced drug delivery systems for use with psychedelic compounds, announce the successful milestone of merging NOVA's psilocybin-based drug development program with Mycrodose's transdermal technology.
Dec 16, 2021 07:30 am ET
Nova Mentis and Mycrodose Therapeutics Announce Major Milestone with Transdermal Technology for Fragile X Syndrome Clinical Program
VANCOUVER, BC, Dec. 16, 2021 /PRNewswire/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, and Mycrodose Therapeutics ("Mycrodose"), a US pharmaceutical company focused on developing advanced drug delivery systems for use with psychedelic compounds, announce the successful milestone of merging NOVA's psilocybin-based drug development program with Mycrodose's transdermal technology.
Dec 02, 2021 09:58 am ET
Nova Mentis to Present at the H.C. Wainwright Psychedelics Conference
VANCOUVER, BC, Dec. 2, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it will present at the H.C. Wainwright Psychedelics Conference on December 6, 2021.
Nov 09, 2021 07:30 am ET
Nova Mentis Files Genetic Neuroinflammatory Disease Patent
Messenger RNA Diagnostic/Treatment Paradigm
Nov 09, 2021 07:30 am ET
Nova Mentis Files Genetic Neuroinflammatory Disease Patent
Messenger RNA Diagnostic/Treatment Paradigm
Nov 04, 2021 08:30 am ET
Nova Mentis to Present at the Wonderland: Miami Psychedelic Conference
VANCOUVER, BC, Nov. 4, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it will present at  Microdose's Wonderland: Miami psychedelic conference, from November 8-9, 2021.
Nov 02, 2021 08:30 am ET
U.S. FDA Approves Nova Mentis Orphan Drug Application
Psilocybin Fragile X Syndrome Treatment
Nov 02, 2021 08:30 am ET
U.S. FDA Approves Nova Mentis Orphan Drug Application
Psilocybin Fragile X Syndrome Treatment
Oct 26, 2021 08:00 am ET
Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome
VANCOUVER, BC, Oct. 26, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce it has received orphan drug designation from the European Medicines Agency (EMA) for its propriety psilocybin drug for the treatment of fragile X syndrome (FXS), the leading genetic cause of symptoms related to autism spectrum disorder (ASD).
Oct 26, 2021 08:00 am ET
Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome
VANCOUVER, BC, Oct. 26, 2021 /PRNewswire/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce it has received orphan drug designation from the European Medicines Agency (EMA) for its propriety psilocybin drug for the treatment of fragile X syndrome (FXS), the leading genetic cause of symptoms related to autism spectrum disorder (ASD).
Oct 19, 2021 08:00 am ET
Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System
Partnership will Create Patented Products for the Treatment of Neuroinflammatory Disorders
Oct 19, 2021 08:00 am ET
Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System
Partnership will Create Patented Products for the Treatment of Neuroinflammatory Disorders
Sep 14, 2021 10:07 am ET
Nova Mentis Applies to US FDA for Psilocybin Orphan Drug Designation Fragile X Syndrome Treatment
VANCOUVER, BC, Sept. 14, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce it has filed an application with the U.S. Food and Drug Administration (FDA) to receive orphan drug designation for its proprietary psilocybin drug to  treat patients with fragile X syndrome (FXS), the most common inherited cause of autism spectrum disorder (ASD).
Sep 09, 2021 09:00 am ET
Nova Mentis to Present at the H.C. Wainwright Global Investment Conference
VANCOUVER, BC, Sept. 9, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for chronic inflammatory disorders, is pleased to announce that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference, from September 13-15, 2021.
Sep 07, 2021 08:00 am ET
Nova Mentis Expands Psilocybin Research Program Targets Obesity and Diabetes
VANCOUVER, BC, Sept. 7, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it is expanding its psilocybin research and development program to target obesity and diabetes.
Aug 12, 2021 08:00 am ET
Nova Mentis Files Fragile X Orphan Drug Designation with European Medicines Agency
VANCOUVER, BC, Aug. 12, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce it has filed for orphan drug designation with the European Medicines Agency (EMA) for its propriety psilocybin drug to help treat patients with fragile X syndrome (FXS), the leading genetic cause of symptoms related to autism spectrum disorder (ASD).
Jul 29, 2021 08:00 am ET
Nova Mentis Files U.S. Patent Application for Psilocybin-Based Therapeutics
VANCOUVER, BC, July 29, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announced it has filed a U.S. provisional patent application for a proprietary manufacturing process for the production of psilocybin and tryptamine analogues, baeocystin and aeruginascin.
Jul 15, 2021 08:00 am ET
Nova Mentis Appoints Dr. Stephen Glazer as Director and Chief Science Officer
VANCOUVER, BC, July 15, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce the appointment of Dr. Stephen Glazer as Director, Chief Science Officer.
Jun 23, 2021 08:00 am ET
Nova Mentis Autism Clinical Study Approved by Canadian Institutional Review Board
VANCOUVER, BC, June 23, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce it has received Canadian approval for its North American autism clinical study.
Jun 10, 2021 08:00 am ET
Nova Mentis to Present at the H.C. Wainwright Psychedelics Conference
VANCOUVER, BC, June 10, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: LIBFF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it will be presenting at the H.C. Wainwright Psychedelics in Psychiatry and Beyond virtual conference on June 17, 2021.
May 06, 2021 08:30 am ET
Nova Mentis Launches Autism Clinical Study
VANCOUVER, BC, May 6, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that its North American autism clinical study has been listed on ClinicalTrials.gov (NCT04869930), a database of privately and publicly funded clinical studies conducted around the world.
Apr 20, 2021 08:00 am ET
Nova Mentis Organizes Autism Data Bank in North America
VANCOUVER, BC, April 20, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it will be organizing a North American autism spectrum disorder (ASD) data bank to support the Company's development of psilocybin-based compounds in the diagnosis and treatment of ASD.
Mar 31, 2021 08:00 am ET
Nova Mentis Establishes Serotonin Research Centre
New Partnership with FourthWall Testing
Mar 29, 2021 08:00 am ET
Nova Mentis Announces Promising Research Results
Psilocybin formulation Modulates Anxiety-Like Behaviour in Rat Autism Model
Mar 10, 2021 07:00 am ET
Nova Mentis Upgrades U.S. Listing to the OTCQB Venture Market
VANCOUVER, BC, March 10, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company that is a global leader in the emerging field of serotonergic psychedelic medicine, is pleased to announce that it has been approved for trading on the OTCQB Venture Market effective today, March 10, 2021.
Mar 03, 2021 07:45 am ET
/R E P E A T -- Nova Mentis Launches Autism Microbiome Study in the United States/
VANCOUVER, BC, March 3, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a leader in the development of psilocybin and other entheogens, is pleased to announce the launch of its US-based Observational Study NM-101: "Microbiotic Diversity in Autism Spectrum Disorder (ASD): Improving Diagnostics by Differentiating Subtypes."
Mar 03, 2021 02:01 am ET
Nova Mentis Launches Autism Microbiome Study in the United States
VANCOUVER, BC, March 3, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a leader in the development of psilocybin and other entheogens, is pleased to announce the launch of its US-based Observational Study NM-101: "Microbiotic Diversity in Autism Spectrum Disorder (ASD): Improving Diagnostics by Differentiating Subtypes."
Feb 25, 2021 07:30 am ET
/R E P E A T -- Nova Mentis Autism Clinical Study Approved by Institutional Review Board/
VANCOUVER, BC, Feb. 25, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a leader in the development of psilocybin and other psychedelic compounds with broad cognitive, behavioral, and peripheral physiologic effects, has received approval for its first clinical program in Autism Spectrum Disorder (ASD). The Company has obtained Institutional Review Board (IRB) approval of its protocol for a US-based Observational Study (NM-101): "Microbiotic Diversity in Autism Spectrum Disorder (ASD): Improving Diagnostics by Differentiating Subty
Feb 25, 2021 02:01 am ET
Nova Mentis Autism Clinical Study Approved by Institutional Review Board
VANCOUVER, BC, Feb. 25, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a leader in the development of psilocybin and other psychedelic compounds with broad cognitive, behavioral, and peripheral physiologic effects, has received approval for its first clinical program in Autism Spectrum Disorder (ASD). The Company has obtained Institutional Review Board (IRB) approval of its protocol for a US-based Observational Study (NM-101): "Microbiotic Diversity in Autism Spectrum Disorder (ASD): Improving Diagnostics by Differentiating Subty
Feb 18, 2021 07:00 am ET
/R E P E A T -- Nova Mentis Expands Pre-Clinical Development Pipeline; Company Begins Fragile X Syndrome Treatment with its Proprietary Psilocybin Drug/
VANCOUVER, BC, Feb. 18, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a leader in the development of serotonergic psychedelic compounds, is pleased to announce that the Company is expanding its pre-clinical program to develop a novel diagnostic and treatment approach to fragile X syndrome (FXS), a persistent unmet medical need.
Feb 18, 2021 02:01 am ET
Nova Mentis Expands Pre-Clinical Development Pipeline; Company Begins Fragile X Syndrome Treatment with its Proprietary Psilocybin Drug
VANCOUVER, BC, Feb. 18, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a leader in the development of serotonergic psychedelic compounds, is pleased to announce that the Company is expanding its pre-clinical program to develop a novel diagnostic and treatment approach to fragile X syndrome (FXS), a persistent unmet medical need.
Feb 11, 2021 07:00 am ET
Nova Mentis Appoints Gary R. Harlem to Scientific Advisory Board
VANCOUVER, BC, Feb. 11, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA" or the "Company"), a leader in the development of serotonergic psychedelic compounds, is pleased to announce that it has appointed Gary R. Harlem to its Scientific Advisory Board, effective immediately.
Feb 09, 2021 07:30 am ET
Feb 09, 2021 02:01 am ET
Jan 26, 2021 07:30 am ET
Jan 26, 2021 02:01 am ET
Jan 25, 2021 07:00 am ET
Nova Mentis to be Listed in the First-Ever Psychedelic Index
VANCOUVER, BC, Jan. 25, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA" or the "Company") is pleased to announce that it has been included in the world's first North American Psychedelic Index. Based on this index, The Horizon Psychedelic Stock Index ETF is expected to commence trading Jan. 27, 2021 under ticker "PSYK" on the NEO Exchange.
Jan 13, 2021 07:00 am ET
Nova Mentis Appoints Dr. Julia V. Perederiy, PhD to Scientific Advisory Board
VANCOUVER, BC, Jan. 13, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA" or the "Company") is pleased to announce that it has appointed Dr. Julia V. Perederiy, PhD to its Scientific Advisory Board, effective immediately.
Jan 04, 2021 07:00 am ET
Nova Mentis Appoints Dr. Kyle Ambert to Scientific Advisory Board
VANCOUVER, BC, Jan. 4, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA" or the "Company") is pleased to announce that it has appointed Dr. Kyle H. Ambert, PhD to its Scientific Advisory Board, effective immediately. Dr. Ambert has also agreed to become a consultant to NOVA and will assist the Company in designing preclinical and clinical autism spectrum disorder (ASD) studies and analyzing their results.
Dec 29, 2020 07:00 am ET
Nova Mentis Expands Psychedelic Drug Pipeline
VANCOUVER, BC, Dec. 29, 2020 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA" or the "Company") is pleased to announce that it has added two additional psychedelic compounds to its drug portfolio. NOVA has contracted with its U.S. partner to begin manufacturing the active pharmaceutical ingredients (API), baeocystin and aeruginascin. NOVA is currently developing C-GMP API psilocybin at its U.S. partner's facility which has highly trained quality control staff on site and certifies all release testing prior to human studies. Per contractual agreements,
Dec 08, 2020 09:55 am ET
IIROC Trade Resumption - NOVA
VANCOUVER, BC, Dec. 8, 2020 /CNW/ - Trading resumes in:
Dec 08, 2020 09:30 am ET
Nova Mentis Uncovers Diagnostic Biomarkers in Preclinical Autism Study
VANCOUVER, BC, Dec. 8, 2020 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA" or the "Company") is pleased to announce that it has uncovered molecular and bacteriologic diagnostic markers in its recently completed preclinical model study of autism spectrum disorder (ASD). This behavioral study, based on prenatal exposure to valproic acid (VPA) in rats, was designed, in conjunction with Dr. Viviana Trezza, Department of Science, Roma Tre University, Rome, Italy, by Pilz Bioscience Corp (Pilz), a wholly-owned subsidiary of NOVA.
Dec 07, 2020 02:59 pm ET
IIROC Trading Halt - NOVA
VANCOUVER, BC, Dec. 7, 2020 /CNW/ - The following issues have been halted by IIROC:
Dec 03, 2020 07:00 am ET
Nova Mentis Appoints Dr. Marvin S. Hausman as Chairman of Scientific Advisory Board
VANCOUVER, BC, Dec. 3, 2020 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA" or the "Company") is pleased to announce that it has appointed Dr. Marvin S. Hausman, MD as Chairman of its Scientific Advisory Board, effective immediately. Dr. Hausman is the Chief Medical Officer of Pilz Bioscience Corp., a wholly-owned subsidiary of NOVA and is leading their research and development efforts in medicinal psychedelics. Dr. Hausman is an immunologist and board-certified urological surgeon with more than 30 years of drug research and development experience with v
Dec 01, 2020 07:00 am ET
/R E P E A T -- Nova Mentis Life Science Completes Acquisition of Pilz Bioscience/
VANCOUVER, BC, Nov. 30, 2020 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA" or the "Company") is pleased to announce that, further to its news releases dated November 2 and November 18, 2020, the amalgamation between Pilz Bioscience Corp. ("Pilz") and 1271642 B.C. Ltd. ("Nova Subco"), a wholly-owned subsidiary of the Company, has been completed (the "Transaction"). 
Nov 30, 2020 04:34 pm ET
Nova Mentis Life Science Completes Acquisition of Pilz Bioscience
VANCOUVER, BC, Nov. 30, 2020 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA" or the "Company") is pleased to announce that, further to its news releases dated November 2 and November 18, 2020, the amalgamation between Pilz Bioscience Corp. ("Pilz") and 1271642 B.C. Ltd. ("Nova Subco"), a wholly-owned subsidiary of the Company, has been completed (the "Transaction"). 
Nov 18, 2020 07:00 am ET
Nova Mentis Life Science Announces Receipt of Pilz Shareholder Approval
VANCOUVER, BC, Nov. 18, 2020 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA" or the "Company") is pleased to announce that, further to its news release dated November 2, 2020, the shareholders of Pilz Bioscience Corp. ("Pilz") have approved the amalgamation agreement between Pilz and 1271642 B.C. Ltd. ("Nova Subco"), a wholly-owned subsidiary of the Company, pursuant to which the Company will acquire all of the issued and outstanding common shares in the capital of Pilz (the "Transaction").
Nov 17, 2020 07:00 am ET
Pilz BioScience Senior Team Members To Participate In Upcoming Microdose Conference
VANCOUVER, BC, Nov. 17, 2020 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA" or the "Company") is pleased to announce that senior members of the Pilz Bioscience Corp. ("Pilz") team will be participating in the upcoming "The Mushroom Conference: A Molecular Masterclass" hosted by Microdose Psychedelic Insights and The Conscious Fund, November 20-22, 2020.
Nov 11, 2020 07:00 am ET
Nova Mentis Life Science Acquisition Target, Pilz Bioscience Corp, Provides Corporate Update
VANCOUVER, BC, Nov. 11, 2020 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA" or the "Company") is pleased to announce that its pending acquisition target, Pilz Bioscience Corp. ("Pilz"), has provided a corporate update. 
Nov 05, 2020 07:00 am ET
Nova Mentis Life Science Acquisition Target, Pilz Bioscience Corp, Signs Psilocybin Manufacturing Agreement
VANCOUVER, BC, Nov. 5, 2020 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA" or the "Company") is pleased to announce that its pending acquisition target, Pilz Bioscience Corp. ("Pilz"), has entered into a psilocybin manufacturing agreement with a U.S. based pharmaceutical company with over 800 employees. Pilz will have complete and sole ownership of the Drug Master File (DMF) which will be used for regulatory submission prior to commencing human clinical trials.  Initial jurisdictions under consideration include United States, Canada and the European Uni
Nov 02, 2020 07:00 am ET
Nova Mentis Life Science Signs Amalgamation Agreement to Acquire 100% of Pilz BioScience Corp.
VANCOUVER, BC, Nov. 2, 2020 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA" or the "Company") is pleased to announce that, further to its news release dated October 9, 2020, it has entered into a definitive amalgamation agreement, (the "Definitive Agreement") with Pilz Bioscience Corp. ("Pilz") and 1271642 B.C. Ltd. ("Nova Subco"), a wholly-owned subsidiary of the Company, pursuant to which the Company will acquire all of the issued and outstanding common shares in the capital of Pilz (the "Transaction"). The Definitive Agreement replaces the letter of i
Oct 13, 2020 08:00 am ET
/R E P E A T -- Nova Mentis Life Science Signs Agreement to Acquire 100% of Psychedelic-Focused Autism Research Company Pilz BioScience Corp./
VANCOUVER, BC, Oct. 9, 2020 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA" or the "Company") is pleased to announce it has signed a non-binding letter of intent ("the LOI") to acquire 100 percent of the issued and outstanding securities of privately-held Pilz Bioscience Corp. ("Pilz") by way of a share exchange or other such business combination as deemed appropriate (the "Transaction"). Pilz is a research driven biotechnology company that aims to develop medicinal psychedelics for neuroinflammatory conditions with a significant cognitive component and
Oct 09, 2020 04:00 pm ET
Nova Mentis Life Science Signs Agreement to Acquire 100% of Psychedelic-Focused Autism Research Company Pilz BioScience Corp.
VANCOUVER, BC, Oct. 9, 2020 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA" or the "Company") is pleased to announce it has signed a non-binding letter of intent ("the LOI") to acquire 100 percent of the issued and outstanding securities of privately-held Pilz Bioscience Corp. ("Pilz") by way of a share exchange or other such business combination as deemed appropriate (the "Transaction"). Pilz is a research driven biotechnology company that aims to develop medicinal psychedelics for neuroinflammatory conditions with a significant cognitive component and
Sep 17, 2020 05:25 pm ET
Former Senior Leader of Apotex Joins Nova Mentis Life Science Board and is Named COO
VANCOUVER, BC, Sept. 17, 2020 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA" or the "Company") is pleased to announce the appointment of Ms. Jacqueline McConnell to its Board of Directors and as Chief Operating Officer ("COO").
Aug 31, 2020 08:00 am ET
Nova Mentis Biotech Corp Signs Psilocybin Research Agreement with France-Based Physiogenex
VANCOUVER, BC, Aug. 31, 2020 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA" or the "Company") is pleased to announce that its wholly-owned subsidiary, Nova Mentis Biotech Corp. ("NMBC") has signed a Master Service Agreement with leading preclinical Contract Research Organization for metabolic disorders, Physiogenex.
Jul 08, 2020 08:00 am ET
Nova Mentis Re-Appoints Robert W.E. Laurie as Advisory Board Chair and Psychedelics Regulatory Advisor
VANCOUVER, BC, July 8, 2020 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFD) ("NOVA" or the "Company") is pleased to announce  Mr. Robert W.E. Laurie has been re-appointed Advisory Board Chair and additionally appointed  Psychedelics Regulatory Advisor.
Jul 02, 2020 08:00 am ET
Nova Mentis Appoints Dr. Aylia Mohammadi to Board of Directors
VANCOUVER, BC, July 2, 2020 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFD) ("NOVA" or the "Company") is pleased to announce that Dr. Aylia Mohammadi has joined the Company's Board of Directors.
Jun 25, 2020 03:21 pm ET
CSE Bulletin: Name and Symbol Change and Consolidation - Liberty Leaf Holdings Ltd. (LIB)
Toronto, Ontario--(Newsfile Corp. - le 25 juin/June 2020) - Liberty Leaf Holdings Ltd. has announced a name change and symbol change to Nova Mentis Life Science Corp. (NOVA) and a consolidation of its issued and outstanding common shares on the basis of one (1) post consolidated common share for every four (4) pre-consolidated common shares.